
DNTH Stock Forecast & Price Target
DNTH Analyst Ratings
Bulls say
Dianthus Therapeutics Inc demonstrates a promising prospective valuation, with recent updates reflecting a $2 increase in their target price, now set at $44. This upward adjustment underscores the market's recognition of the company's innovative pipeline, particularly the development of DNTH103, a novel subcutaneous active C1s antibody targeting severe autoimmune and inflammatory diseases. Additionally, the experienced leadership team further enhances confidence in the company’s ability to navigate the competitive biotech landscape successfully.
Bears say
Dianthus Therapeutics Inc. may face significant challenges in advancing its pipeline due to potential difficulties in raising adequate funds. The reliance on external funding indicates a vulnerability that could stall the development of its key assets, including the subcutaneous active C1s antibody, DNTH103. This financial uncertainty poses a risk to the company's long-term viability and growth prospects in the competitive biotechnology sector.
This aggregate rating is based on analysts' research of Magenta Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
DNTH Analyst Forecast & Price Prediction
Start investing in DNTH
Order type
Buy in
Order amount
Est. shares
0 shares